# US 2013/0156823 A1 · Excipient-free Aerosol Formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156823 A1
- Document ID: US20130156823A1
- Status: Published application
- Kind: A1
- Application number: 13/721,444
- Filed: 2012-12-20
- Published: 2013-06-20
- Earliest claimed: 2011-12-20
- Assignees: MAP Pharmacauticals, Inc.
- Inventors: Libo WU; Wiwik Watanabe
- Web page: https://patentgrep.com/patent/US20130156823A1

## CPC

- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 9/008: {comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]}
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/5517: condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for producing formulations for orally inhaled benzodiazepines that do not require the presence of a surface modifier are described. The formulations are useful in the treatment of epileptic seizures.

## Claims

### Claim 1

A pharmaceutical aerosol formulation comprising: (i) a particulate benzodiazepine; and (ii) a propellant, wherein the aerosol formulation does not contain a surfactant or other surface modifiers.

### Claim 2 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the formulation is stable at 25° C. and 60% relative humidity (RH) conditions for at least 4 weeks.

### Claim 3 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the benzodiazepine is selected from the group consisting of alprazolam, bretazenil, bromazepam, brotizolam, chlordiazepoxide, cinolazepam, clonazepam, cloxazolam, clorazepate, delorazepam, diazepam, estazolam, flunitrazepam, flurazepam, flutoprazepam, halazepam, ketazolam, loprazolam, lorazepam, lormetazepam, medazepam, midazolam, nimetazepam, nitrazepam, nordazepam, oxazepam, phenazepam, pinazepam, prazepam, premazepam, quazepam, temazepam, tetrazepam, triazolam and their pharmaceutically accepted salts.

### Claim 4 (depends on 3)

The pharmaceutical aerosol formulation of claim 3, wherein the benzodiazepine is lorazepam or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane and 1,1,1,2,3,3,3-heptafluoropropane.

### Claim 6 (depends on 5)

The pharmaceutical aerosol formulation of claim 5, wherein the propellant is 1,1,1,2,3,3,3-heptafluoropropane.

### Claim 7 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the benzodiazepine has a mean particle size of about 0.5 microns to about 3 microns.

### Claim 8 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the particulate benzodiazepine has one or more of the following:
(i) a d10 of about 0.5 micron to about 1.0 micron;
(ii) a d50 of about 1.0 micron to about 2.0 microns; or
(iii) a d90 of about 2.0 microns to about 3.0 microns.

### Claim 9 (depends on 1)

The pharmaceutical aerosol formulation of claim 1, wherein the formulation is delivered to a subject using a pressured metered dose inhaler.

### Claim 10 (depends on 9)

The pharmaceutical aerosol formulation of claim 9, wherein the pressured metered dose inhaler is breath-actuated.

### Claim 11

A pharmaceutical aerosol formulation consisting of a particulate benzodiazepine and a propellant, wherein the aerosol formulation is stable at 25° C. and 60% relative humidity (RH) conditions for at least 4 weeks.
